drug discovery
Frog Skin Yields Potent Painkillers, but None Clinic Ready
Frog Skin Yields Potent Painkillers, but None Clinic Ready
Shawna Williams | Jan 1, 2018
Decades after their discovery by bioprospectors, amphibian-derived analgesics continue to attract scientific attention.
Sea Anemone Toxin Could Treat Autoimmunity
Sea Anemone Toxin Could Treat Autoimmunity
Jef Akst | Jan 1, 2018
If successful, the treatments could alleviate patients’ pain by reducing inflammation.
Sourcing Painkillers from Scorpions’ Stings
Sourcing Painkillers from Scorpions’ Stings
Abby Olena | Jan 1, 2018
Compounds in the arachnids’ venom interact with ion channels to both cause and block pain.
Toxin from a Dangerous Fish Delicacy
Toxin from a Dangerous Fish Delicacy
Kerry Grens | Jan 1, 2018
In tiny doses, the pufferfish’s tetrodotoxin can be turned into a pain-relieving ion channel blocker.
Mining Spider Toxins for Analgesic Clues
Mining Spider Toxins for Analgesic Clues
Catherine Offord | Jan 1, 2018
Arachnids harbor a plentiful array of molecules that target mammalian pain receptors.
Researchers Mine Centipede Toxins for Analgesics
Researchers Mine Centipede Toxins for Analgesics
Catherine Offord | Jan 1, 2018
Venomous centipedes may harbor a clue to the creation of a successful pain-killing compound for humans.
Novel Analgesics at a Snail’s Pace
Novel Analgesics at a Snail’s Pace
Bob Grant | Jan 1, 2018
Studying cone snail venom has yielded novel pain pathways, but the peptides that function as toxins are difficult to translate into drugs.
Snake Venoms Cause and Block Pain
Snake Venoms Cause and Block Pain
Kerry Grens | Jan 1, 2018
Painful snake bites may hold clues to developing analgesic drugs.
Image of the Day: Brain Barrier Balls
Image of the Day: Brain Barrier Balls
The Scientist Staff | Jun 7, 2017
In a new and improved in vitro model of the blood-brain barrier, scientists allow a milieu of cells to grow together and form multicellular structures.
RNAi’s Future in Drug-Target Screening
RNAi’s Future in Drug-Target Screening
Catherine Offord | Apr 17, 2017
A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool?